W. Shen

发表

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Depei Wu, Xiaowen Tang, Tianhui Liu, 2021, Journal of Hematology & Oncology.

HLA-DQB1 mismatch increase risk of severe bleeding independently in recipients of allogeneic stem cell transplant

Depei Wu, Yue Han, Meng Zhou, 2021, Annals of Hematology.

TNF‐α increases the risk of bleeding in patients after CAR T‐cell therapy: A bleeding model based on a real‐world study of Chinese CAR T Working Party

Depei Wu, Xiaowen Tang, H. Qiu, 2021, Hematological oncology.

CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia

Hong-jie Shen, L. Yang, Depei Wu, 2022, Experimental Hematology & Oncology.

First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Depei Wu, Xiaowen Tang, Lin Yang, 2018, American journal of cancer research.

Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases

L. Yao, J. Cen, Jinlan Pan, 2022, Molecular carcinogenesis.

Oncogenic FLT3 internal tandem duplication activates E2F1 to regulate purine metabolism in acute myeloid leukaemia.

G. Deng, Ke Wang, W. Shen, 2023, Biochemical pharmacology.

CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation

Depei Wu, Xiaowen Tang, Tianhui Liu, 2020, Journal of Hematology & Oncology.

Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia.

Depei Wu, Xiaowen Tang, Lin Yang, 2018, American journal of cancer research.